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ABSTRACT  
Background: There is limited knowledge about the optimal timing of antiretroviral treatment 
initiation in older children and adolescents.  
Methods: 20,576 antiretroviral treatment (ART) naïve patients, aged 1-16 years at enrolment, 
from 19 cohorts in Europe, Southern and West Africa, were included. We compared mortality 
and growth outcomes for different ART initiation rules, aligned with previous and recent 
WHO criteria, for 5 years of follow-up, adjusting for all measured baseline and time-
dependent confounders using the g-formula. 
Results: Median (1st;3rd percentile) CD4 count at baseline was 676 cells/mm3 (394;1037) 
(children age ≥1 and <5 years), 373 (172;630) (≥5 and <10 years), and 238 (88;425) (≥10 and 
<16 years). There was a general trend towards lower mortality and better growth for earlier 
treatment initiation. In children <10 years old at enrolment, by 5 years of follow-up there was 
lower mortality and higher mean height-for-age z-score with immediate ART initiation versus 
delaying until CD4 count<350 cells/mm3 (or CD4%<15% or weight-for-age z-score<-2) with 
absolute differences in mortality and height-for-age z-score of  0.3% (95% CI: 0.1%;0.6%) and 
-0.08 (-0.09;-0.06) (≥1 and <5 years), and 0.3% (0.04%;0.5%) and -0.07 (-0.08;-0.05) (≥5 and 
<10 years). In those age >10 years at enrolment we did not find any difference in mortality or 
growth with immediate ART initiation with estimated differences of -0.1% (-0.2%;0.6%) and -
0.03 (-0.05;0.00) respectively.  Growth differences in children <10 years persisted for 
treatment thresholds using higher CD4 values. Regular follow-up led to better height and 
mortality outcomes.  
Conclusions: Immediate ART is associated with lower mortality and better growth for up to 5 
years in children <10 years old. Our results on adolescents were inconclusive.  
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Key messages 
 We found lower mortality and better growth for immediate versus delayed 
antiretroviral treatment initiation in children <10 years of age after 5 years of follow-
up. 
 We showed neither benefits nor harms for immediate treatment initiation in 
adolescents aged 10-16. 
 The best outcomes were observed in European children who attained growth 
outcomes comparable to HIV negative children. The effects for the different ART 
initiation criteria were similar in Southern Africa, West Africa, and Europe. 
 Irregular clinic visits led to worse outcomes but the comparative effectiveness of 
different ART initiation criteria were not affected 
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INTRODUCTION 
The World Health Organization’s (WHO) recommendations on when to start treatment in 
children and adolescents have changed substantially in recent years. In 2006, antiretroviral 
treatment (ART) was only recommended for children and adolescents with advanced or 
severe HIV-associated clinical disease or if CD4 count (or CD4%) fell below an age-
dependent critical value.(1, 2) Reasons for delaying therapy initiation were due to concerns 
about toxicities, non-adherence, drug resistance, logistical challenges, cost considerations, 
and limited future options for patients failing therapy.(3-8)  
An increasing body of evidence from recent years suggests that delaying ART initiation for 
too long may be harmful: the results of the CHER trial, which showed a striking mortality 
benefit for immediate ART initiation in children less than 3 months of age, prompted WHO 
to recommend ART in all HIV positive children presenting under the age of 1.(9) CD4 
treatment-initiation thresholds for older children and adolescents persist, but were 
gradually increased in 2010 and 2013(10-12): from 2013 WHO recommended ART for  
children older than 5 years, and non-pregnant adolescents with asymptomatic or mild 
clinical disease when CD4 count is below 500 cells/mm3. Children younger than 5 years were 
to be started immediately irrespective of CD4 count. These changes were motivated by 
programmatic considerations as well as the results of the PREDICT trial and causal modelling 
studies which suggested no harm from immediate treatment initiation.(13-17) The newly 
released WHO 2015 guidelines recommend universal ART for all.(18) 
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However, large evidence gaps remain: the PREDICT trial enrolled children aged 1-12 years 
but was underpowered (due to the lower than expected event rate) and did not include 
older adolescents.(15) Causal modelling studies only included children younger than 5 
years.(16, 17) The optimal timing of treatment initiation in adolescents, a key population in 
the HIV epidemic, is unknown. This is concerning as findings from adult studies, including 
the morbidity benefit associated with immediate ART found in the START and TEMPRANO 
trials(19, 20), may not apply to adolescents due to different lifestyle factors, adherence, 
modes of infections, and the effects of puberty. Moreover, all the above studies implicitly 
assume that children come for regular visits, typically 3 monthly. It is possible that in real-
world settings (with less frequent or missed visits and lag in ART initiation after meeting the 
treatment initiation criteria) the effect of different treatment initiation criteria differs from 
idealized study conditions. Also, there is no data after 3 years of follow-up but possible 
disadvantages of immediate treatment initiation may only be visible in the long term, for 
example for children failing multiple treatments or with drug complications. In addition, all 
mentioned studies evaluate criteria which are not exactly identical and comparable to WHO 
criteria. 
Given the future shift in WHO guidelines to universal ART for everyone, it would be ethically 
challenging to conduct a trial on the “when to start” question, hence we attempted to 
address the above evidence gaps by analysing observational data from West Africa, 
Southern Africa and Europe, adjusting for time-dependent confounders affected by prior 
treatment using the g-formula.(21-24) We chose the g-formula since traditional multivariate 
regression techniques may yield biased treatment effect estimates in our context. We 
compared mortality and growth outcomes for different treatment initiation rules, aligned 
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with previous and recent WHO criteria, for patients 1-16 years of age and with up to 5 years 
of follow-up. We consider both a best case scenario, which uses similar assumptions to 
other studies regarding visit frequency and prompt ART initiation once treatment thresholds 
are met, and an alternative scenario which uses assumptions that aim to resemble the real-
world situation in some of our cohorts.  
METHODS 
Study population 
We used data from 19 cohorts of the IeDEA Southern Africa, IeDEA West Africa and COHERE 
in EuroCoord collaborations, representing 11 countries (Supplementary Table 1).(25-29)  All 
contributing cohorts obtained ethical approval from the relevant institutions before 
submitting anonymized patient data to the networks.  Patients ≥1 year of age and 
presenting before their 16th birthday were included if their first clinic visit was no earlier 
than 1 January 1996 to ensure that every patient received combination antiretroviral 
therapy, and those that received antiretrovirals had at least one pre-ART visit recorded. 
Database closure was 31 December 2014.  
Variables and Definitions 
For our analysis we used children’s age at enrolment, health care facility, sex, date of ART 
initiation, year of enrolment as well as CD4 count, CD4%, weight-for-age z-scores (WAZ, if 
≤10 years), and BMI-for-age z-scores (BMIAZ, if ≥5 years) - both at time of enrolment and 
during follow-up. The outcomes variables were height-for-age z-score (HAZ) and death.  
Most sites measured supine length until a child was comfortable to stand, though some 
sites worked with supine length until the age of 2. All z-scores were based on WHO 
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definitions, i.e. standards developed by the WHO Multicenter Growth Reference Study 
conducted between 1997 and 2003 in multifaceted settings.(30) Motivated by historic 
initiation criteria we defined the following three age groups: 1-5 years (AG1, ≥1 and <5 
years), 5-10 years (AG2, ≥5 and <10 years), and 10-16 years (AG3, ≥10 and <16 years).  
Follow-up data was evaluated in three-monthly intervals for a period of up to 5 years.  Data 
were defined to be missing if no data were available for a particular interval. Children were 
defined as lost to follow-up (LTFU), and censored, if LTFU was confirmed or if at the time of 
database closure they had no contact with their health care facility for at least 12 months 
since their last recorded visit.   
We carried forward previous values for missing CD4 count, CD4%, WAZ, and HAZ follow-up 
data until a patient was censored or died. To deal with missing baseline data we used the 
Expectation-Maximization-Bootstrap algorithm for multiple imputation.(31) The imputation 
model included all baseline and follow-up variables (including lagged and lead versions of 
them), death, LTFU, both a carry-forward and attended visit indicator variable, and region. 
The algorithm accounted for the non-linear and longitudinal structure of the data.  
Statistical analyses 
Both baseline and follow-up data were summarized with medians (first;third quartile) and 
by proportions (categorical data). HAZ trajectories, stratified by age and region, were 
displayed smoothly using additive models.(32, 33)  
We used the g-formula(21-23) to estimate cumulative mortality and growth (mean HAZ) for 
up to 5 years follow-up for different treatment initiation criteria. The criteria differ by age 
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group and are based on recent and old guidelines, see Table 1 for a comprehensive 
overview.  
[Table 1 here] 
With the g-formula we took into account time-dependent confounding affected by prior 
treatment. Time-dependent variables which affected both treatment assignment and the 
outcome were clinical stage, CD4 count, and CD4% (for children ≤10). We followed the 
approach of previous work(16, 17) and approximated stage with WAZ (BMIAZ for AG3) since 
many stage defining events in our context, such as persistent diarrhoea or tuberculosis, are 
likely to affect a child’s weight. Our algorithm implementing the g-formula required 
comprehensive model fitting for the time-varying variables and the outcome, which we 
utilized using additive models, non-linear interactions, and model selection (Supplementary 
Textbox 1). 
In our main analysis we used similar assumptions as Schomaker et al.(16): we estimated all 
counterfactual outcomes under no administrative censoring, no loss to follow-up, full 
adherence to the regime, immediate ART initiation after reaching eligibility, and regular 
(three monthly) follow-up. We further assumed no unmeasured confounding and no model 
misspecification. We present results separately for each age group and for all patients 
presenting with a CD4 count>500 cells/mm3. In an alternative secondary analysis we 
changed our assumptions: we do not assume regular follow-up, but rather infrequent 
follow-up which we modeled based on the visit frequency in our data. In addition, we 
assumed that treatment is started at one visit after reaching eligibility; see Supplementary 
Textbox 1 and other work for implementation details.(16, 34, 35) To explore whether our 
implicit assumptions of correct model specification and non-informative censoring were 
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likely met or not we compared the estimates of the g-formula under no treatment strategy 
(“natural course scenario”) with the observed data. All results are presented with 95% 
nonparametric bootstrap confidence intervals (CI). Our analyses were implemented in R.(36) 
RESULTS 
Descriptive Results 
From the 20,576 patients included in our study most came from the youngest age group 
(42.1%) and from Southern Africa (78.9%). The median follow-up time was 900 (366;1827) 
days and 37.2% of our patients did not start ART during follow-up (Table 2). About 29%, 
35%, and 7% of patients met our LTFU definition in Southern Africa, West Africa, and Europe 
respectively. Most deaths (53.7%) occurred during the first 6 months after the first visit 
(Supplementary Table 2).  
[Table 2 here] 
Both baseline and follow-up characteristics differed markedly between regions and age 
groups (Table 2, Supplementary Table 3): European children presented with substantially 
higher CD4 count, CD4%, WAZ, HAZ, and BMIAZ than African children. Children from both 
African regions had similar baseline characteristics though West African children had higher 
HAZ but lower WAZ at baseline. Older children had lower CD4 counts and lower CD4% than 
younger children. All characteristics improved gradually during follow-up (Supplementary 
Table 3). Of note, the shape of growth trajectories were very similar for all three regions but 
differed by age group: children aged 1-5 showed clear improvement during the whole 
follow-up period while growth in children aged 5-10 plateaued after 2-3 years. On average, 
adolescents showed a slow but steady increase in mean HAZ (Figure 1).  
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[Figure 1 here] 
About 79.1% of the European adolescents were confirmed perinatally infected and for 
13.2% the mode of infection was unknown. We had no data on mode of infection for African 
adolescents. 
G-formula analyses 
Our implementations of the g-formula were in general able to reproduce the relevant data 
characteristics in the natural course scenario (Supplementary Figures 8-9). Some deviations 
for the mean HAZ measurements in the fifth year of follow-up for AG2 indicate caution with 
respect to these results. We therefore report only results up to four years for the growth 
analysis of this age group. 
There was a trend towards lower mortality and better growth for earlier treatment initiation 
(Figures 2-4, Supplementary Figure 7). The mortality differences between immediate ART 
initiation and thresholds using CD4 count≤350 cells/mm3 were clear in children ≤10 years, 
but not very clear for higher thresholds and for adolescents (95% CIs in Table 3a). Growth 
differences with respect to different treatment interventions were more pronounced than 
the mortality differences, suggesting clear benefits of immediate ART initiation in all age 
groups. 
[Table 3 here, Figures 2-4 here] 
Patients presenting with CD4 count>500 cells/mm3 had lower mortality and higher mean 
HAZ values than other patients (Figures 2-4). The mortality and growth differences at 5 
years for immediate ART initiation versus delaying ART until CD4 count <750 cells/mm3 (or 
CD4%<25% or WAZ<-2), as shown in Figure 2, were 0% (-0.1%;0.3%) and 0.03 (0.01;0.04) for 
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AG1. Comparing immediate ART initiation with deferring ART until CD4 count<500 
cells/mm3 (or WAZ<-2), as shown in Figures 3 and 4, yields differences of 0.4% (0.1%;0.6%) 
and 0.10 (0.07;0.12) for AG2 and 0.1% (-0.1%;0.9%) and 0.06 (-0.01;0.09) for AG3.  
In our alternative scenario, with infrequent visits and slightly delayed treatment assignment, 
mortality was typically higher and the mean HAZ lower than in our main scenario. However, 
the comparative effectiveness of the different interventions was in general similar, and was 
slightly attenuated only in a few comparisons (Table 3).  
Our results for the effectiveness of the different treatment interventions were consistent in 
all three regions (Figure 5, Supplementary Figures 1-6). As in the raw data, results were best 
for European patients, followed by West African patients when looking at growth and South 
African patients when evaluating mortality. 
[Figure 5 here] 
DISCUSSION 
Statement of principal findings 
Our study suggests better growth and lower or equal mortality for early ART initiation in 
children <10 years, but results were inconclusive for adolescents. Outcomes were better, 
with more pronounced benefits of immediate ART initiation, for children presenting with 
CD4≥500 cells/mm3 and under regular follow-up assumptions. The comparative 
effectiveness of the different initiation criteria was similar in all regions and for irregular 
follow-up and slightly delayed initiation.  
Strengths of the study 
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We included a large study population from three different contexts of HIV care which 
enabled us to investigate the generalizability of our results. Our choice of treatment 
initiation criteria and assumptions provide both a good comparison to WHO criteria and 
former trials and modelling studies. Moreover, the present study is the first one to include 
adolescents, to evaluate outcomes after 3 years, and the first one to contrast estimates 
from idealized and more realistic settings. We believe that our results therefore give a 
comprehensive and concise overview on the implications of the timing of ART in children 
and adolescents. 
Limitations 
We were constrained with respect to the availability of some data: our African cohorts did 
not collect regular information on clinical stage, the outcomes of children LTFU were not 
known, and we had missing baseline data. Moreover, we did not look at secondary 
outcomes such as immune recovery and other morbidity measures. 
To deal with the unavailability of stage data we used WAZ as a proxy measure. This may be 
appropriate as argued in other studies (16, 17), but for adolescents we had to use BMIAZ 
since there are no WHO based z-scores for weight. BMIAZ may not respond as quickly to 
clinically severe events as WAZ, but the results from the natural course scenario 
(Supplementary Figure 9) gives some re-assurance of its use. In general, our sensitivity 
checks suggest that we may be able to estimate our outcomes reasonably well and that 
unmeasured confounding and model misspecification may not be severe in our analysis, 
though these assumptions can never be tested completely from the data. The g-formula can 
deal with LTFU as long as censoring is uninformative. However, we cannot exclude the 
possibility that particularly sick children get lost and die soon thereafter - possibly because 
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some of them may stay with caregivers struggling to maintain adherence and clinic visits. 
Absolute mortality estimates and comparisons between regions should therefore be 
interpreted with caution. We have successfully imputed missing baseline data. Patients with 
missing data may have different characteristics and therefore outcomes, but comparisons 
between interventions may not differ much as suggested in another study.(16) 
Interpretation of the study 
Our study highlights the heterogeneity and characteristics of the different age groups in our 
cohorts.  
The youngest age group consists of infants who were infected perinatally. This group is 
affected by high early mortality, but those who survive can expect steady improvement in 
height with immediate ART initiation and in Europe even up to the level of HIV-uninfected 
children.  
Older children, aged 5-10, are long term survivors who tend to present at health care 
facilities much sicker than younger children. Since they are long term survivors, their early 
mortality after presentation is not as high. However, likely because of the longer time 
period they have been exposed to HIV, it may be more difficult to restore their immune 
system and other physiological functions which in turn results in slower growth. Two to 
three years after presentation, when the children have reached an age of 8-13 years, their 
growth slows down as seen in both the raw data and the counterfactual outcomes. This 
could be explained by a delay in the start of puberty.(37, 38) It is not surprising that 
immediate ART initiation proves to have the most beneficial effect compared to the other 
criteria in this age group. 
14 
 
Adolescents comprise a mixed population of long term perinatally infected survivors and 
some newly sexually infected patients. Their growth trajectories look different from those of 
younger patients, but potential changes in adolescence, for example lifestyle and 
adherence, may complicate comparisons. Moreover, the poor baseline characteristics and 
overall high mortality highlights the vulnerability of this group. It remains unclear whether 
behavioural factors or baseline characteristics drive the results of this age group, in 
particular the identical results for immediate ART initiation and delayed initiation until CD4 
count<350 cells/mm3. 
Another important finding is that, irrespective of the treatment strategy, growth is better 
and mortality lower, when patients have frequent visits and start ART as soon as they are 
eligible. It is not surprising that this is the case, but the differences we found quantify this 
benefit and highlight how results from trials need to be interpreted carefully when 
translated into policy in real-world settings. Moreover, it shows the importance of retaining 
children in regular care to achieve optimal treatment outcomes. 
Results in context 
The comparative effectiveness of the different treatment strategies in the youngest age 
group is almost identical to a recent causal modelling study which included a subset of our 
data (compare Figure2a,c with Figures 3 and 4 in Schomaker et al.(16)). Smaller differences, 
particularly with respect to our higher and smoother growth curves, can be explained by 
different sample sizes, the inclusion of European data, and small differences with respect to 
eligibility criteria, LTFU definitions and imputation models.    
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The PREDICT trial, enrolling Asian children aged 1-12, showed no mortality benefit between 
immediate ART initiation and deferring ART until either the CD4% was below 15% or any 
CDC category C event occurred. The trial did however show better height gain for children 
who start ART immediately. Our results support the claim that immediate ART initiation 
enhances growth in children. However, our results also suggest mortality benefits of 
immediate ART initiation in older children. The differences of the two studies may be 
because of (i) the small number of children aged 5-10 and (ii) the lower than expected event 
rate in the trial. The mortality benefit we have found is small in absolute terms and it would 
be surprising to see this effect in a trial with only few events which, in addition, did not 
enrol many children aged 5-10. Moreover, the children in the trial presented healthier than 
ours and eligibility criteria differed, i.e. only children with CD4% between 15% and 24% were 
considered in the trial.  
We did not find major negative consequences of delaying initiation of ART in adolescents 
until immunological criteria are met, even when considering a threshold of 350 cells/mm3 or 
restricting to individuals with a high CD4 count at baseline. This yields similar interpretations 
to a recent causal modelling study conducted in over 50,000 adults in North America and 
Europe.(39)  Preliminary findings from the START and TEMPRANO trials point towards a 
morbidity benefit of immediate ART initiation, but, as Lodi et al.(39) have also highlighted, 
different populations with different co-infections, different follow-up times, and different 
assumptions complicate comparisons between different settings. Furthermore, findings 
from adults can likely not be transferred to adolescents due to different patient care 
systems, durations of infection, issues with non-adherence, drug combinations, and lifestyle 
factors.  It remains important to couple ART initiation strategies with appropriate patient 
16 
 
adherence and support strategies to reduce the risk of treatment failure and to monitor 
neurodevelopmental progress. 
Conclusions 
Immediate ART initiation is likely of benefit for all children ≤10 years. However, more 
research on adolescents and long term outcomes is required.  
Figure Legends 
Figure 1: Estimated growth trajectories in the raw data, stratified by region and age group.  
Figure 2: Cumulative mortality and mean HAZ for children ≥1 and <5 years. Results are 
displayed for different intervention strategies and patient groups. 95% bootstrap confidence 
intervals for absolute estimates and estimated differences between strategies are listed in 
Table 3a.  All results were obtained using the g-formula. Treatment thresholds refer to CD4 
count (<350/750), CD4% (<15%/25%), and WAZ (< -2). Panels B and D are restricted to 
patients presenting with CD4 count > 500 cells/mm3. 
Figure 3: Cumulative mortality and mean HAZ for children aged ≥5 and <10 years. Results 
are displayed for different intervention strategies and patient groups. 95% bootstrap 
confidence intervals for absolute estimates and estimated differences between strategies 
are listed in Table 3a.  All results were obtained using the g-formula. Treatment thresholds 
refer to CD4 count (<200/350/500) and WAZ (< -2). Panels B and D are restricted to patients 
presenting with CD4 count > 500 cells/mm3. 
Figure 4: Cumulative mortality and mean HAZ for adolescents aged ≥10 and <16 years. 
Results are displayed for different intervention strategies and patient groups. 95% bootstrap 
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confidence intervals for absolute estimates and estimated differences between strategies 
are listed in Table 3a.  All results were obtained using the g-formula. Treatment thresholds 
refer to CD4 count (<200/350/500). Panels B and D are restricted to patients presenting 
with CD4 count > 500 cells/mm3. 
Figure 5: Mean HAZ and cumulative mortality overall and for different regions, stratified by 
age group. Treatment thresholds refer to CD4 count (<200/350/500/750), CD4% (15%/25%), 
and WAZ (< -2). 
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